164341-39-3

Usage

Uses

Used in Pharmaceutical Industry:
C-(5-Trifluoromethyl-pyridin-2-yl)-methylamine is used as a reagent for the preparation of azaquinazolinecarboxaminde derivatives, which are known as p70S6K inhibitors. These inhibitors play a significant role in the development of therapeutic agents targeting various diseases, including cancer and other proliferative disorders. The compound's ability to form azaquinazolinecarboxaminde derivatives with potential biological activities makes it a valuable asset in the pharmaceutical industry.
Used in Chemical Synthesis:
In addition to its applications in the pharmaceutical industry, C-(5-Trifluoromethyl-pyridin-2-yl)-methylamine can also be utilized in the synthesis of other chemical compounds with diverse applications. Its unique structure and reactivity make it a versatile building block for the development of new molecules with potential uses in various fields, such as materials science, agrochemistry, and environmental science.

Upstream product

• 80194-70-3 3-chloro-2-cyano-5-(trifluoromethyl)pyridine 
• 326476-49-7 [3-chloro-5-(trifluoromethyl)-pyridin-2-yl]methanamine hydrochloride 
• 95727-86-9 2-cyano-5-trifluoro-methylpyridine 
• 871826-12-9 1-[5-(trifluoromethyl)pyridin-2-yl]methanamine hydrochloride 
• 50488-42-1 2-bromo-5-(trifluoromethyl)pyridine 

Relevant academic research and scientific papers

Synthesis and Optimization of Kv7 (KCNQ) Potassium Channel Agonists: The Role of Fluorines in Potency and Selectivity

Based on the potent Kv7 agonist RL-81, we prepared new lead structures with greatly improved selectivity for Kv7.2/Kv7.3 over related potassium channels, i.e., Kv7.3/Kv7.5, Kv7.4, and Kv7.4/7.5. RL-36 and RL-12 maintain an agonist EC2x of ca. 1 μM on Kv7.2/Kv7.3 in a high-throughput assay on an automated electrophysiology platform in HEK293 cells but lack activity on Kv7.3/Kv7.5, Kv7.4, and Kv7.4/7.5, resulting in a selectivity index SI > 10. RL-56 is remarkably potent, EC2x 0.11 ± 0.02 μM, and still shows an SI = 2.5. We also identified analogues with significant selectivity for Kv7.4/Kv7.5 over Kv7.2/Kv7.3. The extensive use of fluorine in iterative core structure modifications highlights the versatility of these substituents, including F, CF3, and SF5, to span orders of magnitude of potency and selectivity in medicinal chemistry lead optimizations.

Preparation method of 2-aminomethyl-5-trifluoromethylpyridinium salt

The invention discloses a preparation method of 2-aminomethyl-5-trifluoromethylpyridinium salt, and belongs to the technical field of pesticides and medical intermediates. According to the method, 2-cyano-3-chloro-5-trifluoromethylpyridine is taken as a raw material, hydrogenation is carried out in an alcohol solvent and an acid in the presence of a metal catalyst, molecular dechlorination is carried out while nitrile group hydrogenation is carried out, and the product 2-aminomethyl-5-trifluoromethylpyridinium salt is obtained after treatment. The method has the advantages of reasonable technical route selection, short reaction steps, mild reaction conditions, low raw material cost and high separation yield, and is suitable for industrial amplification.

Carbamate compounds

Carbamate compounds having a structure represented by formula I (where R1, R2, R3, R4, R5 and R6 are as defined herein) are useful as anti-tumor agents.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity, wherein X1, X2, X3, X4, X5, R5, R6, R7, R8a, R8b, R9, Z1, Z2 and L are as defined in the description.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor

Compounds of formula (I) are novel VR1 antagonists that are useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence and bladder overactivity.

Novel process for the preparation of 2-aminomethylpyridine derivative

Process for the preparation of 2-aminomethylpyridine derivative of general formula (I) or a salt thereof : ???in which :n represents 0, 1, 2 or 3,X is halogen atom,each Y may be the same or different and may be a halogen atom, a halogenoalkyl, an alkoxycarbonyl or an alkylsulphonyl.